Skip to main content
Premium Trial:

Request an Annual Quote

Cancer MDx Firm Nucleix Raises $5M

NEW YORK (GenomeWeb) – Israeli epigenetics-based diagnostics firm Nucleix announced on Monday that it has raised more than $5 million in private financing.

The company's lead product is the urine-based Bladder EpiCheck for detecting bladder cancer. The funding will go toward clinical trials for the test, as well as efforts to gain European CE marking and US Food and Drug Administration regulatory approval, Tel Aviv, Israel-based Nucleix said. Funds will also be used to develop diagnostic tests for other cancers.

OrbiMed invested more than $4 million in the funding round, while entrepreneur and private investor Zohar Zisapel and angel investors also participated in the raise. It is the first time Nucleix has raised funding from a venture capital fund since being founded in 2008, it said.

The company also appointed Opher Shapira as president and COO. Shapira was a founder of cancer screening firm BioView, where he also served as president and CEO.

The Scan

Panel Votes for COVID-19 Pill

A US Food and Drug Administration panel has voted to support the emergency use authorization of an antiviral pill for COVID-19 from Merck and Ridgeback Biotherapeutics, CNN says.

But Not Harm

New Scientist reports that UK bioethicists say that though gene editing may improve food production, it should not harm livestock welfare.

Effectiveness Drop Anticipated

Moderna's Stéphane Bancel predicts that that current SARS-CoV-2 vaccines may be less effective against the Omicron variant, the Financial Times reports.

Cell Studies of Human Chromatin Accessibility, SARS-CoV-2 Variants, Cell Signaling Networks

In Cell this week: chromatin accessibility maps of adult human tissues, modeling to track SARS-CoV-2 variants of concern, and more.